Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway.
Hidemasa KawabataYusuke OnoNobue TamamuraKyohei OyamaJun UedaHiroki SatoKenji TakahashiKenzui TaniueTetsuhiro OkadaSyugo FujibayashiAkihiro HayashiTakuma GotoKatsuro EnomotoHiroaki KonishiMikihiro FujiyaKeita MiyakawaMishie TaninoYuji NishikawaDaisuke KogaTsuyoshi WatanabeChiho MaedaHidenori KarasakiAndrew S LissYusuke MizukamiToshikatsu OkumuraPublished in: Journal of gastroenterology (2022)
Oncogenic GNAS induces mucin production, not only via MUC2 but also via MUC5AC/B, which may enlarge cystic lesions in the pancreas. The mutation may also limit tumor aggressiveness by attenuating NOTCH signaling; therefore, such tumor-suppressing effects must be considered when therapeutically inhibiting the GNAS pathway.